Lasa Supergenerics Board of Directors

Get the latest insights into the leadership at Lasa Supergenerics. Learn about the experienced professionals guiding the company's strategy and governance.

NamePosition
Dr. Omkar Pravin Herlekar Chairman & Managing Director
Mr. Umesh S Pawar Executive Director
Mr. Ajay Sukhwani Independent Director
Ms. Manali Bhagtani Independent Director
Ms. Ekta Gurnasinghani Independent Director
Mr. Hardesh Tolani Independent Director

Lasa Supergenerics Share price

LASA

8.8

0.06 (0.69%)
NSE
BSE
Last updated on 4 Sep, 2025 | 15:31 IST
BUYSELL
Today's High

9.15

Today's Low

8.53

52 Week Low

8.16

52 Week High

33.49

The current prices are delayed, login to your account for live prices

Lasa Supergenerics FAQs

The board at Lasa Supergenerics consists of experienced professionals, including Dr. Omkar Pravin Herlekar , Mr. Umesh S Pawar , and others, overseeing the company’s strategic and corporate governance.

Directors at Lasa Supergenerics are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.

As of the latest update, Dr. Omkar Pravin Herlekar is the current chairman at Lasa Supergenerics.

Executive directors at Lasa Supergenerics are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.

Yes, Lasa Supergenerics adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.

At Lasa Supergenerics, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.